Omalizumab (Xolair): Anti-Immunoglobulin E Treatment in Allergic Diseases

Handbook of Therapeutic Antibodies

Volumn 3, Issue , 2008, Pages 951-997

  Kroegel, Claus ^a   Foerster, Martin ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Allergic diseases; Disorders; Omalizumab; Sinusitis; Therapeutic agent

Indexed keywords

EID: 84889464340     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527619740.ch37     Document Type: Chapter

References (128)

1. Adelroth, E., Rak, S., Haahtela, T., Aasand, G., Rosenhall, L., Zetterstrom, O., Byrne, A., Champain, K., Thirwell, J., Della Gioppa, G., Sandstrom T. (2000), Recombinant humanized mAb E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 106: 253-259.
2. Allam, J.P., Niederhagen, B., Bücheler, M., Appel, T., Betten, H., Bieber, T., Bergé, S., Novak, N. (2006) Comparative analysis of nasal and oral mucosa dendritic cells. Allergy 61: 166-172.
3. Amiri, P., Haak-Frendscho, M., Robbins, K., Mckerrow, J.H., Stewart, T., Jardieu, P. (1994) Anti-immunoglobulin E treatment decreases worm burden and egg production in Schistosoma mansoni-infected normal and interferon gamma knockout mice. J Exp Med 180: 43-51.
4. Aubrey, J.P., Pochon, S., Graber, P., Jansen, K.U., Bonnefoy, J.Y. (1992) CD21 is a ligand for CD23 and regulates IgE production. Nature 358: 505-507.
5. Ayres, J.G., Higgins, B., Chilvers, E.R., Ayre, G., Blogg, M., Fox H. (2004) Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-tosevere) allergic asthma. Allergy 59: 701-708.
6. Bang, L.M., Plosker, G.L. (2004) Omalizumab: a review of its use in the management of allergic asthma. Treat Respir Med. 3: 183-199.
7. Barnes, P.J. (2000) Anti-IgE therapy in asthma: rationale and therapeutic potential. Int Arch Allergy Immunol 123: 196-204.
8. Beasley, R., Crane, J., Lai, C.K., Pearce, N. (2000) Prevalence and etiology of asthma. J Allergy Clin Immunol 105(Suppl.): S466-S472.
9. Bieber, T., de la Salle, H., Wollenberg, A., Hakimi, J., Chizzonite, R., Ring, J., et al. (1992) Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (FcεRI). J Exp Med 175: 1285-1290.
10. Bonnefoy, J.Y., Plater-Zyberk, C., Lecoanet-Henchoz, S., Gauchat, J.F., Aubry, J.P., Graber, P. (1996) A new role for CD23 in inflammation. Immunol Today 17: 418-420.
11. Borkowski, T.A., Jouvin, M.H., Lin, S.Y., Kinet, J.P. (2001) Minimal requirements for IgE-mediated regulation of surface FcεRI. J Immunol 167: 1290-1296.
12. Boulet, L.P., Chapman, K.R., Cote, J., Kalra, S., Bhagat, R., Swystun, V.A., Laviolette, M., Cleland, L.D., Deschesnes, F., Su, J.Q., DeVault, A., Fick, R.B., Cockcroft, D.W. (1997) Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 155: 1835-1840.
13. Boushey, H.A. (2001) Experiences with monoclonal antibody therapy for allergic asthma. J Allergy Clin Immunol 108: S77-S83.
14. Bousquet, J., Wenzel, S., Holgate, S., Lumry, W., Freeman, P., Fox, H. (2004) Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 125: 1378-1386.
15. Bousquet, J., Cabrera, P., Berkman, N., et al. (2005) The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 60: 302-308.
16. Burrows, B., Martinez, F.D., Halonen, M., Barbee, R.A., Cline M.G. (1989) Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 320: 271-277.
17. Busse, W., Coren, J., Lanier, B.Q., McAlary, M., Fowler-Taylor, A., Della Cioppa, G., van As, N., Gupta, N. (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108: 184-190.
18. Buhl, R., Hanf, G., Soler, M., Bensch, G., Wolfe, J., Everhard, F., et al. (2002) The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 20: 1088-1094.
19. Casale, T.B., Bernstein, I.L., Busse, W.W., LaForce, C.R., Tinkelman, D.G., Stoltz, R.R., Dockhorn, R.J., Reimann, J., Su, J.Q., Fick, R.B., Adelman, D.C. (1997) Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 100: 110-121.
20. Casale, T., Condemi, J., Miller, S., Fickm, R.B., Jr., McAlarym, M., Fowler-Taylor, A., Gupta N. (1999) rhuMAb-E25 in the treatment of seasonal allergic rhinitis (SAR). Ann Allergy Asthma Immunol 82: 75-82.
21. Chang, T.W. (2000) The pharmacological basis of anti-IgE therapy. Nat Biotechnol 18: 157-163.
22. Chang, T.W., Davis, F.M., Sun, N.C., Sun, C.R., Macglashan, D.W., Jr., Hamilton, R.G. (1990) Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases. Biotechnology (NY) 8: 122-126.
23. Chervinsky, P., Casale, T., Townley, R., et al. (2003) Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 91: 1607.
24. Corren, J., Casale, T., Deniz, Y., Ashby, M. (2003) Omalizumab, a recombinant humanized antiIgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 111: 87-90.
25. Dacus, J.J. (2003) Disease of the month: asthma. PEC Update 3: 4-6.
26. D'Amato, G., Holgate, S. (2002) The Impact of Air Pollution on the Respiratory Health. Monograph of the European Respiratory Society. Sheffield, UK.
27. D'Amato, G., Oldani, V., Donner, C.F. (2002) Anti-IgE monoclonal antibody: a new approach to the treatment of allergic respiratory diseases. Arch Chest Dis 59: 29-33.
28. D'Amato, G., Liccardi, G., Noschese, P., Salzillo, A., D'Amato, M., Cazzola, M. (2004) Anti-IgE Monoclonal antibody (Omalizumab) in the treatment of atopic asthma and allergic respiratory diseases. Curr Drug Targets-Inflammation Allergy 3: 227-231.
29. Davis, F.M., Gossett, L.A., Chang, T.W. (1991) An epitope on membrane-bound but not secreted IgE: implications in isotypespecific regulation. Biotechnology (NY) 9: 53-56.
30. Davis, F.M., Gossett, L.A., Pinkston, K.L., Liou, R.S., Sun, L.K., Kim, Y.W., Chang, N.T., Chang, T.W., Wagner, K., Bews, J., et al. (1993) Can anti-IgE be used to treat allergy? Semin Immunopathol 15: 51-73.
31. Djukanovic, R., Wilson, S.J., Kraft, M., Jarjour, N.N., Steel, M., Chung, K.F., Bao, W., Fowler-Taylor, A., Matthews, J., Busse, W.W., Holgate, S.T., Fahy, J.V. (2004) Effects of treatment with antiimmunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 170: 583-593.
32. Easthope, S., Jarvis, B. (2001) Omalizumab. Drugs 61: 253-260.
33. Eray, M., Tuomikoski, T., Wu, H., Nordstrom, T., Andersson, L.C., Knuutila, S., et al. (1994) Cross-linking of surface IgG induces apoptosis in a bcl-2 expressing human follicular lymphoma line of mature B cell phenotype. Int Immunol 6: 1817-1827.
34. Fahy, J.V., Fleming, H.E., Wong, H.H., Liu, J.T., Su, J.Q., Reimann, J., Fick, R.B., Boushey, H.A. (1997) The effect of an anti-IgE monoclonal antibody on the early-and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155: 1828-1834.
35. Feuchtinger, T., Bartz, H., von Berg, A., Riedinger, F., Brauburger, J., Stengle, S., et al. (2003) Treatment with omalizumab normalizes the number of myeloid dendritic cells during the grass pollen season. J Allergy Clin Immunol 111: 428-430.
36. Finn, A., Gross, G., van Bavel, J., et al. (2003) Omalizumab improves asthmarelated quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 111: 278-284.
37. Food and Drug Administration, Center for Biologics Evaluation and Research. (2003) BLASTN 103976/0, review of clinical safety data: original BLS submitted on June 2, 2000 and response to complete review letter submitted on December 18, 2002. Rockville, Md.: Department of Health and Human Services.
38. Fox, J.A., Hotaling, T.E., Struble, C., Ruppel, J., Bates, D.J., Schoenhoff, M.B. (1996) Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 279: 1000-1008.
39. Garman, S.C., Kinet, J.P., Jardetzky, T.S. (1998) Crystal structure of the human high-affinity IgE receptor. Cell 95: 951-961.
40. Garman, S.C., Wurzburg, B.A., Tarchevskaya, S.S., Kinet, J.P., Jardetzky, T. S. (2000) Structure of the Fc fragment of human IgE bound to its high-affinity receptor FcepsilonRI alpha. Nature 406: 259-266.
41. Geha, R.S., Jabara, H.H., Brodeur, S.R. (2003) The regulation of immunoglobulin E class-switch recombination. Nat Rev Immunol 3: 721-732.
42. GINA-Global Initiative for Asthma. (1995, updated 2002, 2003). Global strategy for asthma management and prevention. NIH publication number 02-3659.
43. Gounni, A.S., Lamkhioued, B., Delaporte, E., Dubost, A., Kinet, J.P., Capron, A., et al. (1994) The high-affinity IgE receptor on eosinophils: from allergy to parasites or from parasites to allergy? J Allergy Clin Immunol 94: 1214-1216.
44. Gounni, A.S., Wellemans, V., Yang, J., Bellesort, F., Kassiri, K., Gangloff, S., et al. (2005) Human airway smooth muscle cells express the high affinity receptor for IgE (Fc epsilon RI): a critical role of Fc epsilon RI in human airway smooth muscle cell function, J Immunol 175: 2613-2621.
45. Hagan, P., Blumenthal, U.J., Dunn, D., Simpson, A.J., Wilkins, H.A. (1991) Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium. Nature 349: 243-245.
46. Hamilton, R.G., Marcotte, G.V., Saini, S.S. (2005) Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy. J Immunol Methods 303: 81-91.
47. Herbelin, A., Elhadad, S., Ouaaz, F., de Groote, D., Descamps-Latscha, B. (1994) Soluble CD23 potentiates interleukin-1-induced secretion of interleukin-6 and interleukin-1 receptor antagonist by human monocytes. Eur J Immunol 24: 1869-1873.
48. Henchoz, S., Gauchat, J.F., Aubry, J.P., Graber, P., Pochon, S., Bonnefoy, J.Y. (1994) Stimulation of human IgE production by a subset of anti-CD21 monoclonal antibodies: requirement of a co-signal to modulate epsilon transcripts. Immunology 81: 285-290.
49. Heusser, C., Jardieu, P. (1997) Therapeutic potential of anti-IgE antibodies. Curr Opin Immunol 9: 805-813.
50. Hochhaus, G., Brookman, L., Fox, H., et al. (2003) Pharmacodynamics of omalizumab: implications for optimized dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 19: 491-498.
51. Holgate, S.T. (1998) Asthma and allergy-disorders of civilization? Q J Med 91: 171-184.
52. Holgate, S.T., Bousquet, J., Wenzel, S., Fox, H., Liu, J., Castellsague, J. (2001) Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 17: 233-240.
53. Holgate, S.T., Casale, T., Wenzel, S., Bousquet, J., Deniz, Y., Reisner, C. (2005a) The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 115: 459-465.
54. Holgate, S.T., Djukanovic, R., Casale, T., Bousquet, J. (2005b) Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 35: 408-416.
55. Humbert, M., Beaskey, R., Ayres, J., Slavin, R., Hebert, J., Bousquet, J., Beeh, K.M., Ramos, S., Canonica, G.W., Hedgecock, S., Fox, H., Blogg, M., Surrey, K. (2005) Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60: 309-316.
56. ISAAC-Steering Committee. (1998) Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 351: 1225-1232.
57. Ishizaka, K., Ishizaka, T. (1970) Biological function of IgE antibodies and mechanisms of reaginic hypersensitivity. Clin Exp Immunol 6: 25-31.
58. Joshua, A., Boyce, J.A. (2006) Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol 117: 1415-1418.
59. Kalinski, P., Hilkens, C.M., Wierenga, E.A., Kapsenberg, M.L. (1999) T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 20: 561-567.
60. Kehry, M.R., Yamashita, L.C. (1989) Lowaffinity IgE receptor (CD23) function on mouse B cells: role in IgE-dependent antigen focusing. Proc Natl Acad Sci USA 86: 7556-7560.
61. Kelly, H.W., Sorkness, C.A. (2002) Asthma. In: Dipiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, L.M. (Eds.), Pharmacotherapy: a pathophysiologic approach. 5th edn. New York: McGraw-Hill, pp. 475-510.
62. Kijimoto-Ochiai, S. (2002) CD23 (the lowaffinity IgE receptor) as a C-type lectin: a multidomain and multifunctional molecule. Cell Mol Life Sci 59: 648-664.
63. Kolbinger, F., Saldanha, J., Hardman, N., Bendig, M.M. (1993) Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies. Protein Eng 6: 971-980.
64. Kraft, S., Katoh, N., Novak, N., Koch, S., Bieber, T. (2001) Unexpected functions of FcepsilonRI on antigen-presenting cells. Int Arch Allergy Immunol 124: 35-37.
65. Kroegel, C. (2002) Bronchial asthma. Pathogenic basis, diagnostic and therapy. 2nd edn. Thieme, Stuttgart, New York.
66. Kroegel, C., Mock, B., Reißig, A., Hengst, U., Förster, M., Machnik, A., Henzgen, M. (2002) Antibodies in allergic diseases. Selective inhibition of IgE-mediated reactions by humanized IgE-anti-IgEantibodies. Arzneimitteltherapie 20: 226-237.
67. Kroegel, C., Reissig, A., Henzgen, M. (2004) Therapeutic dosing of omalizumab = 20x[IgE]: is this equation correct or is enough too less? Pneumologie 58: 543-545.
68. Kuehr, J., Brauburger, J., Zielen, S., Schauer, U., Kamin, W., et al. (2002) Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 109: 274-280.
69. Lanier, B.Q., Corren, J., Lumry, W., Liu, J., Fowler-Taylor, A., Gupta, N. (2003) Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 91: 154-159.
70. Lemanske, R.F., Nayak, A., McAlary, M., Everhard, F., Fowler-Taylor, A., Gupta, N. (2002) Omalizumab improves asthmarelated quality of life in children with allergic asthma. Pediatrics 110: E55.
71. Leung, D.Y., Sampson, H.A., Yunginger, J.W., Burks, A.W., Schneider, L.C., Wortel, C.H., et al. (2003) Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348: 986-993.
72. Leynadier, F., Doudou, O., Gaouar, H., Le Gros, V., Bourdeix, I., Guyomarch-Cocco, L., Trunet, P. (2004) Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 113: 360-361.
73. Lin, H., Boesel, K.M., Griffith, D.T., et al. (2004) Omalizumab rapidly decreases nasal allergic response and FceRI on basophils. J Allergy Clin Immunol 113: 297-302.
74. Liu, J., Lester, P., Builder, S., Shire, S.J. (1995) Characterization of complex formation by humanized anti-IgE antibody and monoclonal IgE Biochemistry 34: 10474-10482.
75. Liu, Y.J., Kanzler, H., Soumelis, V., Gilliet, M. (2001) Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol 2: 585-589.
76. MacGlashan, D., Jr. (2005) IgE and Fc{epsilon}RI regulation. Ann N Y Acad Sci 1050: 73-88.
77. MacGlashan, D.W., Bochner, B.S., Adelman, D.C., Jardieu, P.M., Togias, A., Lichtenstein, L.M. (1997a) Serum IgE level drives basophil and mast cell IgE receptor display. Int Arch Allergy Immunol 113: 45-47.
78. MacGlashan, D.W., Jr., Bochner, B., Adelman, D., Jardieu, P., Togias, A., McKenzie-White, J., Sterbinsky, S., Hamilton, R., Lichtenstein, L.M. (1997b) Down-regulation of FceRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 158: 1438-1445.
79. MacGlashan, D., McKenzie-White, J., Chichester, K., et al. (1998) In vitro regulation of FceRI expression on human basophils by IgE antibody. Blood 91: 1633-1643.
80. Maizels, N. (2003) Yin outwits yang at the IgE locus. Nat Immunol 4: 7-8.
81. Maizels, R.M., Yazdanbakhsh, M. (2003) Immune regulation by helminth parasites: cellular and molecular mechanisms. Nat Rev Immunol 3: 733-744.
82. Malveaux, F.J., Conroy, M.C., Adkinson, N.F.J., Lichtenstein, L.M. (1978) IgE receptors on human basophils: Relationship to serum IgE concentration. J Clin Invest 62: 176-181.
83. Masoli, M., Fabian, D., Holt, S., Beasley, R. (2004) Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59: 469-478.
84. Maurer, D., Ebner, C., Reininger, B., Fiebiger, F., Kraft, D., Kinet, J.P., et al. (1995) The high affinity IgE receptor (FcεRI) mediates IgE-dependent allergen presentation. J Immunol 154: 6285-6290.
85. Maurer, D., Ebner, C., Reininger, B., Petzelbauer, P., Fiebiger, E., Stingl, G. (1997) Mechanisms of Fc epsilon RI-IgEfacilitated allergen presentation by dendritic cells. Adv Exp Med Biol 417: 175-178.
86. Milgrom, H., Fick, R.B., Jr., Su, J.Q., Reimann, J.D., Bush, R.K., Watrous, M.L., et al. (1999) Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 341: 1966-1973.
87. Milgrom, H., Berger, W., Nayak, A., Gupta, N., Pollard, S., McAlary, M., Fowler-Taylor, A., Rohane, P. (2001) Treatment of childhood asthma with antiimmunoglobulin E antibody (omalizumab). Pediatrics 108: 36-45.
88. Nakamura, T., Kloetzer, W.S., Brams, P., Hariharan, K., Chamat, S., Cao, X., LaBarre, M.J., Chinn, P.C., Morena, R.A., Shestowsky, W.S., Li, Y.P., Chen, A., Reff, M.E. (2002) In vitro IgE inhibition in B cells by anti-CD23 monoclonal antibodies is functionally dependent on the immunoglobulin Fc domain. Int J Immunopharmacol 22: 131-141.
89. National Heart, Lung, and Blood Institute. (1997) National Asthma Education and Prevention Program Expert Panel Report 2: guidelines for the diagnosis and management of asthma. Bethesda, Md.: National Institutes of Health (Publication no. 97-4051).
90. National Heart, Lung, and Blood Institute. (2003) Education and Prevention Program Expert Panel Report: guidelines for the diagnosis and management of asthma-update on selected topics 2002. Bethesda, Md.: National Institutes of Health (Publication no. 02-5074).
91. Nissim, A., Eshhar, Z. (1992) The human mast cell receptor binding site maps to the third constant domain of immunoglobulin E. Mol Immunol 29: 1065-1072.
92. Nissim, A., Schwarzbaum, S., Siraganian, R., Eshhar, Z. (1993) Fine specificity of the IgE interaction with the low and high affinity Fce receptor. J Immunol 150: 1365-1374.
93. Noga, O., Hanf, G., Kunkel, G. (2003) Immunological changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 131: 46-52.
94. Noga, O., Hanf, G., Brachmann, I., Klucken, A.C., Kleine-Tebbe, J., Rosseau, S., Kunkel, G., Suttorp, N., Seybold, J. (2006) Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 117: 1493-1499.
95. Novak, N., Bieber T. (2003) Allergic and nonallergic forms of atopic diseases. Allergy Clin Immunol 112: 252-262.
96. Novak, N., Bieber, T., Katoh N. (2001) Engagement of FcεRI on human monocytes induces the production of IL-10 and prevents their differentiation in dendritic cells. J Immunol 167: 797-804.
97. Omalizumab (Xolair): an anti-IgE antibody for asthma. (2003) Med Lett Drugs Ther 45: 67-68.
98. Package insert. (2003) Xolair (omalizumab). East Hanover, NJ: Aventis, June 2003.
99. Parks, K.W., Casale, T.B. (2006) Anti-immunoglobulin E monoclonal antibody administered with immunotherapy. Allergy Asthma Proc 27(2 Suppl.1): S33-S36.
100. Platts-Mills, T.A. (2001) The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 164(8 Pt 2): S1-S5.
101. Plewako, H., Arvidsson, M., Petruson, K., Oancca, I., Holmberg, K., Adelroth, E.A., Gustafsson, H., Sandstrom, T., Rak, S. (2002) The effect of omalizumab on nasal allergic inflammation, J Allergy Clin Immunol 110: 68-71.
102. Presta, L.G., Lahr, S.J., Shields, R.L., Porter, J.P., Gorman, C.M., Fendly, B.M., Jardieu, P.M. (1993) Humanization of an antibody directed against IgE. J Immunol 151: 2623-2632.
103. Presta, L.G., Shields, R.L., O'Connell, L., Lahr, S., Porter, J., Gorman, C., et al. (1994) The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 269: 26368-26373.
104. Prussin, C., Griffith, D.T., Boesel, K.M., Lin, H., Foste, B., Casale, T.D. (2003) Omalizumab treatment downregulates dendritic cell FceRI expression, J Allergy Clin Immunol 112: 1147-1154.
105. Rambasek, T., Kavuru, M.S. (2006) Omalizumab dosing via the recommended card versus use of the published formula. J Allergy Clin Immunol 117: 708-709.
106. Rissoan, M.C., Soumelis, V., Kadowaki, N., Grouard, G., Briere, F., de Waal Malefyt, R., et al. (1999) Reciprocal control of T helper cell and dendritic cell differentiation. Science 283: 1183-1186.
107. Rolinck-Werninghaus, C., Hamelmann, E., Keil, T., Kulig, M., Koetz, K., Gerstner, B., et al. (2004) The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy 59: 973-979.
108. Rosenwasser, L.J., Meng, J. (2005) Anti-CD23. Clin Rev Allergy Immunol 29: 61-72.
109. Saban, R., Haak-Frendscho, M., Zine, M., Ridgway, J., Gorman, C., Presta, L., Bjorling, D., Saban, M., Jardieu, P. (1994) Human FceRI-IgG and humanized anti-IgE monoclonal antibody MaE11 block passive sensitization of human and rhesus monkey lung. J Allergy Clin Immunol 94: 836-843.
110. Saini, S.S., MacGlashan, D. (2002) How IgE upregulates the allergic response. Curr Opin Immunol 14: 694-697.
111. Saini, S.S., MacGlashan, D.W., Jr., Sterbinsky, S.A., et al. (1999) Downregulation of human basophil IgE and FcεRI surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 162: 5624-5630.
112. Scharenberg, A.M., Kinet, J.P. (1995) Early events in mast cell signal transduction. Chem Immunol 61: 72-87.
113. Shields, R.L., Whether, W.R., Zioncheck, K., O'Connell, L., Fendly, B., Presta, L.G., Thomas, D., Saban, R., Jardieu, P. (1995) Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 107: 308-312.
114. Soler, M., Matz, J., Townley, R., Buhl, R., O'Brien, J., Fox, H., Thirlwell, J., Gupta, N., Della Cioppa, G. (2001) The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics, Eur Respir J 18: 254-261.
115. Sutton, B.J., Gould, H.J. (1993) The human IgE network. Nature 366: 421-428.
116. Stingl, G., Maurer, D. (1997) IgE-mediated allergen presentation via FceRI on antigenpresenting cells. Int Arch Allergy Immunol 113: 24-29.
117. Turner, H., Kinet, J.P. (1999) Signalling through the high-affinity IgE receptor FcεRI. Nature 402(Suppl.): B24-B30.
118. Upham, J.W. (2003) The role of dendritic cells in immune regulation and allergic airway inflammation. Respirology 8: 1408-1418.
119. Vercelli, D., Helm, B., Marsh, P., Padlan, E., Geha, R.S., Gould, H. (1989) The B-cell binding site on human immunoglobulin E. Nature 338: 649-651.
120. Vigo, P.G., Girgis, K.R., Pfuetze, B.L., Critchlow, M.E., Fisher, J., Hussain, I. (2006) Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 55: 168-170.
121. Walker, S., Monteil, M., Phelan, K., Lasserson, T.J., Walters, E.H. (2004) Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 3: CD003559.
122. Wang, B., Rieger, A., Kilgus, O., Ochiai, K., Maurer, D., Fodinger, D., et al. (1992) Epidermal Langerhans cells from normal human skin bind monomeric IgE via FcεRI. J Exp Med 175: 1353-1365.
123. Warner, G.L., Scott, D.W. (1991) A polyclonal model for B cell tolerance. I. Fc-dependent and Fc-independent induction of nonresponsiveness by pretreatment of normal splenic B cells with anti-Ig. J Immunol 146: 2185-2191.
124. Warner, G.L., Gaur, A., Scott, D.W. (1991) A polyclonal model for B-cell tolerance. II. Linkage between signaling of B-cell egress from G0, class II upregulation and unresponsiveness. Cell Immunol 138: 404-412.
125. Warner, J.O., Kaliner, M.A., Crisci, C.D., Del Giacco, S., Frew, A.J., Liu, G.H., Maspero, J., Moon, H.B., Nakagawa, T., Potter, P.C., Rosenwasser, L.J., Singh, A.B., Valovirta, E., Van Cauwenberge, P. (2006) World Allergy Organization Specialty and Training Council. Allergy practice worldwide: a report by the World Allergy Organization Specialty and Training Council. Int Arch Allergy Immunol 139: 166-174.
126. Yazdanbakhsh, M., van den Biggelaar, A., Maizels, R.M. (2001) Th2 responses without atopy: immunoregulation in chronic helminth infections and reduced allergic disease. Trends Immunol 22: 372-377.
127. Xolair product labeling. Genentech, Inc. Accessed January, 2004, at: http://www.gene.com/gene/common/inc/pi/xolair.jsp.
128. Food and Drug Administration Web site. Patient safety news: first biologic for allergy-related asthma. Available at: www.accessdata.gov/scripts/cdrh/cfdocs. Accessed November 15, 2004